Sanofi says its vaccines R&D pipeline raises the bar

French pharma major Sanofi (Euronext: SAN) hosted a Vaccines Investor Event today, when it reaffirmed its ambition to deliver more than 10 billion euros ($10.89 billion) in annual vaccines sales by 2030, driven by core franchises of influenza, meningitis, and pediatric vaccines, with the addition of RSV.

Sanofi also said it intent to start at least five innovative Phase III vaccine programs by 2025. Sanofi said it has made strides in bolstering its vaccines R&D, including the rapid development of a leading-edge mRNA platform, coupled with a global footprint of industrial and commercial expertise.

Thomas Triomphe, executive vice president, Vaccines, Sanofi, commented: “Today, we’re pleased to showcase how vaccines R&D is significantly contributing to the continued growth of the company through the design, development, and delivery of vaccines that address unmet needs. The pace of our innovation is buoyed both by a sense of urgency to address existing public health needs at multiple stages in life, and by our continued transformation as a company that simply won’t accept ‘good enough.”